Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, metastatic

4151 - First line hormone therapy vs chemotherapy for HR+ HER2- metastatic breast cancer in the phase III STIC CTC trial: clinical choice and validity of CTC count


09 Oct 2016


Breast cancer, metastatic


Francois-Clement Bidard


Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365


F. Bidard1, E. Brain1, W. Jacot2, T. Bachelot3, S. Ladoire4, H. Bourgeois5, A. Gonçalves6, H. Naman7, J. Gligorov8, F. Dalenc9, C. Levy10, M. Espie11, J. Ferrero12, E. Luporsi13, M. Sablin1, C. Dubot1, M. Chevrier14, F. Berger14, C. Alix-Panabieres15, J. Pierga1

Author affiliations

  • 1 Medical Oncology, Institut Curie, 75248 - Paris/FR
  • 2 Department Of Medical Oncology, Institut du Cancer de Montpellier (ICM), 34298 - Montpellier/FR
  • 3 Service Oncologie Medicale, Centre Léon Bérard, Lyon/FR
  • 4 Medical Oncology, Centre Georges-François Leclerc (Dijon), Dijon/FR
  • 5 Oncology, Clinique Victor Hugo Le Mans, Le Mans/FR
  • 6 Oncologie Médicale, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 7 Department Of Medical Oncology, Centre azuréen de Cancérologie, Mougins/FR
  • 8 Medical Oncology, APHP, CancerEst, Tenon University Hospital, Paris/FR
  • 9 Medical Oncology, Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse/FR
  • 10 Oncology, Centre Francois Baclesse, Caen/FR
  • 11 Medical Oncology, Assistance Publique - Hopitaux De Paris, Paris/FR
  • 12 Medical Oncology, Centre Antoine Lacassagne, Nice/FR
  • 13 Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy/FR
  • 14 Biostatistics, Institut Curie, 75248 - Paris/FR
  • 15 Laboratory Of Rare Human Circulating Tumor Cells, University Medical Center of Montpellier, 34830 - Montpellier/FR


Abstract 4151


In patients (pts) diagnosed with HR+ HER2- metastatic BC the choice between by front-line hormone therapy (HT, favored option) or chemotherapy (CT) is based on prognostic factors that are overpassed by CTC count. The STIC CTC trial is a large multicentric phase III randomized trial comparing two strategies to choose the front-line treatment type: decision by clinician vs by CTC levels.


Clinical/pathological characteristics were registered at time of inclusion, together with the a priori treatment preferred by clinicians (HT or CT). CTC count was then performed by CellSearch® and pts were randomized between a priori treatment and CTC-driven treatment (HT if


This analysis was performed on 530 randomized pts. Main adverse prognostic factors were PS = 2 or 3 (7%), liver (20%) or pleuropulmonary (37%) metastases, >= 3 metastatic sites (34%), lymphocytopenia (39%). HT was the a priori treatment for 371 pts (70%) and CT for 159 pts (30%). Characteristics independently associated with the a priori choice were: age (p = 0.01), center (p 


In the absence of any predictive factor, treatment decision is influenced by numerous prognostic factors, among which CTC count appears to play a central role. Patients are followed up to compare the outcome of CTC-driven decision vs a priori clinical decision.

Clinical trial identification


Legal entity responsible for the study

Institut Curie




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings